People Behind the Science
869: Developing Extracellular Vesicle Treatments to Address Brain Aging and Inflammation - Dr. Ashok Shetty
Why It Matters
Understanding and harnessing EVs could revolutionize therapy for Alzheimer’s and other age‑related brain disorders, offering a potentially safer and more targeted alternative to traditional drugs. As the U.S. faces a growing elderly population and a $1 trillion economic burden from dementia, breakthroughs in this field are urgently needed and could dramatically improve quality of life for millions.
Key Takeaways
- •Neural stem cell EVs reduce brain inflammation in Alzheimer's models
- •Intranasal EV delivery improves memory and mood in early disease
- •EVs calm overactive microglia without impairing phagocytosis
- •Middle‑age EV treatment may prevent cognitive decline
- •Shetty’s career illustrates translational stem‑cell research success
Pulse Analysis
Dr. Ashok Shetty, distinguished professor at Texas A&M, leads a regenerative‑medicine program focused on extracellular vesicles (EVs) from human neural stem cells. These nanoscale particles carry micro‑RNAs and proteins that modulate neural activity, offering a novel biologic for neurodegenerative disorders. With Alzheimer’s affecting roughly 7 million Americans and lacking disease‑modifying therapy, Shetty’s intranasal EV platform targets neuroinflammation while preserving normal brain function. His work bridges basic neuroscience and translational therapeutics, positioning EVs as a potential breakthrough in brain‑aging interventions.
The approach also aligns with growing interest in non‑invasive brain therapeutics. Preclinical studies from 2024‑2025 show intranasal stem‑cell EVs sharply reduce microglia and astrocyte activation in early‑onset Alzheimer’s mouse models. The treatment lowers amyloid‑beta‑42 plaques, prevents tau tangles, and sustains cognition without hindering microglial phagocytosis. Importantly, the EVs cross the blood‑brain barrier efficiently after nasal administration. A follow‑up experiment demonstrated EVs protect human neurons from toxic amyloid oligomers, and middle‑aged mice receiving EVs exhibited less "brain fog" and slower memory decline. These results suggest EVs can both mitigate existing pathology and act as a preventative strategy for age‑related cognitive loss.
For investors, Shetty’s EV program offers a high‑value pipeline with clear regulatory routes. Intranasal delivery simplifies formulation and improves patient compliance, lowering manufacturing complexity versus intravenous biologics. Funding from the Department of Defense and Veterans Affairs diversifies support, while upcoming trials in sporadic Alzheimer’s—accounting for 80 % of cases—aim to confirm efficacy. Successful translation could unlock a multi‑billion‑dollar market for disease‑modifying Alzheimer’s therapies and expand into other neuroinflammatory disorders, making EVs attractive for strategic partnerships and venture capital. Early data suggest a favorable safety profile, further de‑risking commercial development.
Episode Description
Dr. Ashok K. Shetty is a University Distinguished Professor in the Department of Cell Biology and Genetics and Associate Director of the Institute for Regenerative Medicine at Texas A&M University, Naresh Vashisht College of Medicine. He is developing treatments for neurological and neurodegenerative disorders using stem cells and stem cell-derived products, such as extracellular vesicles. These are tiny vesicles secreted by stem cells that carry microRNAs and proteins. Once they make their way into the brain, they can induce beneficial changes in neural cells to improve brain function. Science takes up a lot of Ash's time, but when he's able to get a moment to himself, he enjoys spending time with family, cycling on a stationary bicycle, playing brain games like Sudoku, and going out to see movies at the theater. Ash earned his Ph.D. in Neuroscience from the All India Institute of Medical Sciences in New Delhi, and he completed postdoctoral research at Montana State University and Duke University. Afterward, he joined the faculty at Duke University in the Division of Neurosurgery. He joined the faculty at Texas A&M University College of Medicine in 2011. In 2024, he was honored with the University Distinguished Professor Award from Texas A&M University, and he has also received the College of Medicine's Senior Research Excellence Award. In addition, Ash is a Fellow of the American Association for the Advancement of Science and the American Society for Neural Transplantation and Repair. He has received the Research Career Scientist Award from the United States Department of Veterans Affairs, has been recognized among the "World's Top 1% of Scientists" across all scientific fields, and he was the 2025 honoree of Fast Company's World Changing Ideas. In this interview, Ash shares details about his life and his work in science.
Comments
Want to join the conversation?
Loading comments...